Evaluation of the Effect of ATX-101 on QT/QTc Intervals
NCT01706679
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
218
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
ATX-101 (10 mg/ml)
DRUG:
ATX-101 (20 mg/ml)
DRUG:
Moxifloxacin (400 mg)
DRUG:
Placebo vehicle (PBS)
Sponsor
Kythera Biopharmaceuticals